APA (7th ed.) Citation

Sengupta, S., Takhar, M., Lin, Y., Manier, S., Baz, R. C., Juluri, K. R., . . . Martin, N. (2024). Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3. Journal of clinical oncology, 42(16_suppl), 7529. https://doi.org/10.1200/JCO.2024.42.16_suppl.7529

Chicago Style (17th ed.) Citation

Sengupta, Sanhita, et al. "Validation of Prototype Biomarkers to Identify Risk Factors of Inflammatory Adverse Events (iAEs) Following Idecabtagene Vicleucel (ide-cel) Infusion in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) in KarMMa-3." Journal of Clinical Oncology 42, no. 16_suppl (2024): 7529. https://doi.org/10.1200/JCO.2024.42.16_suppl.7529.

MLA (9th ed.) Citation

Sengupta, Sanhita, et al. "Validation of Prototype Biomarkers to Identify Risk Factors of Inflammatory Adverse Events (iAEs) Following Idecabtagene Vicleucel (ide-cel) Infusion in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) in KarMMa-3." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. 7529, https://doi.org/10.1200/JCO.2024.42.16_suppl.7529.